About us

As part of Coegin Pharma, a Nordic biotech hub & spoke company with a broad pipeline of innovative dermacosmetic products and pioneering drug candidates for the treatment of diabetes complications and cancer, the company Follicum AB aim to launch a novel and proprietary dermacosmetic product series in 2025.

Management and Board of Directors

John Zibert.

John Zibert

Chief Medical Officer

  • Extensive experience in drug discovery, development, marketing and health-tech.
  • Former founder and CEO at the digital CRO Studies&Me, Chief Medical Officer at LEO Innovation Lab, Head of Medical Affairs EU+ LEO Pharma A/S.
  • Ph.D. in immunology/medicine, M.Sc. human biology and medicine. Academic focus within dermatology, Oncology, Cancer Biology, and health-tech.
  • Vast experience in clinical study design and execution, dermatology, oncology, research and development, innovation processes, medical affairs, marketing. Teaching in clinical trials.
  • Business Mentor for Female Tech Frontrunner and Rockstart.  
Lars Rasmussen.

Lars Rasmussen

Chief Financial Officer

  • Extensive experience in the entire pharmaceutical value chain, from medical development, commercialization, financial management and accounting as well as general management.
  • Previous senior positions for LEO Pharma A/S, both in Denmark and the USA at vice president level, and as CFO and COO for Pila Pharma AB.
  • Veterinary Medicine Doctor (VMD) at the University of Copenhagen, Denmark, B.Sc. in Business Administration with a focus on financial management and accounting at the University of Southern Denmark, Denmark, and Executive MBA at Henley Business School, United Kingdom.
Jens Eriksson.

Jens Eriksson

Chairman of the Board

  • Biotech investor and senior consultant with focus on communication and business development.
  • Long experience as a leader of large retail companies.
  • Key skills in business development, mergers, rationalization, marketing strategy and human resources.
  • M.Sc. in financing, B.Sc. in biomedical engineering and EFL executive education.
  • Currently also CEO of Coegin Pharma AB.
  • Currently also Member of the Board of Coegin Pharma AB.
Jan Nilsson.

Jan Nilsson

Board Member

  • Clinical professor at the University of Lund.
  • World renowned researcher within diabetes and diabetes complications.
  • Deeply involved in the research into Coegin Pharma’s peptide technology.
  • Led the research leading to the discovery of the unique mode of action behind FOL005.